What Florida’s New Child Medication Guidance Gets Right, and What It Risks
Last updated:
If you have ever left a fifteen-minute appointment holding a prescription for your child and a longer list of questions than you walked in with, this story is about that moment. On July 24, the Florida Department of Health issued guidance urging providers to evaluate children thoroughly, look at sleep, screens, play, and diet, and offer psychotherapy before psychiatric medication in most cases for ages 5 to 17. The loudest reactions cast it as either an attack on children’s medicine or a long-overdue rescue from it. Both frames fail parents. The useful questions sit underneath, and much of the science needed to answer them is older than the controversy.
TL;DR
On July 24, 2026, the Florida Department of Health issued non-binding guidance recommending comprehensive evaluation, lifestyle assessment, and psychotherapy before psychotropic medication for children ages 5 to 17 in most cases.
The guidance covers medications for anxiety, depression, attention-deficit related conditions, and behavioral concerns, and advises gradual, supervised reduction rather than abrupt discontinuation.
Coverage cited federal survey data: nearly 15 percent of children ages 5 to 17 received mental health treatment in the prior year, about 8 percent took medication, and 11.5 percent received therapy or counseling.
The American Academy of Pediatrics’ 2019 guideline makes parent training in behavior management first-line for ages 4 to 6 and recommends medication together with behavioral support for ages 6 to 12.
The American Academy of Child and Adolescent Psychiatry warned in May 2026 that messaging which broadly challenges established diagnoses and evidence-based treatments poses risks to children and families.
Florida’s health department now urges thorough evaluation, lifestyle review, and therapy before psychiatric medication for children ages 5 to 17. Here is what the guidance changes, what the science has said for years, and the questions worth bringing to your child’s next appointment.
Common questions
Does Florida’s new guidance mean my child has to stop their medication?
No. The guidance is non-binding and is addressed to health care providers, not families. It changes no prescriptions and creates no requirements. It explicitly recommends gradual, supervised reduction rather than abrupt discontinuation where a change is appropriate. Never stop or adjust a child’s psychiatric medication without the prescribing clinician’s supervision.
What does pediatric guidance actually say about therapy versus medication for children?
For attention challenges, the American Academy of Pediatrics’ 2019 guideline recommends parent training in behavior management as the first-line approach for ages 4 to 6, with medication considered only if behavioral approaches fall short and impairment is significant. For ages 6 to 12 it recommends FDA-approved medication together with behavioral support, not either one alone. For mild symptoms of anxiety or low mood, starting with psychotherapy is a widely accepted approach. The right answer for an individual child comes from an individual evaluation, not from a headline.
What should a thorough evaluation include before starting a psychiatric medication?
Florida’s guidance lists the elements worth asking about anywhere: a full medical, mental health, and physical evaluation; a look at sleep, screen time, unstructured play, physical activity, and diet; laboratory testing where an underlying medical condition is plausible; and attention to stressors at home and school. Keep the tools straight, too. A screening checklist is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing, or medical cause, a professional evaluation is the route to those supports.
How do I raise these questions without putting my child’s doctor on the defensive?
Frame it as partnership, because it is. Try: “Before we decide, help me understand what we have ruled out” and “If we start this, what therapy or skill-building goes with it, and how will we know in three months whether it is working?” Good clinicians welcome engaged parents; the AAP guideline itself treats parents as active participants in care. A provider who bristles at careful questions is giving you useful information as well.
The guidance, announced at a youth mental health roundtable in Orlando, covers medications prescribed to children ages 5 to 17 for anxiety, depression, attention-deficit related conditions, and behavioral concerns. It asks providers to complete a thorough medical, mental health, and physical evaluation before starting medication except in emergencies, to assess sleep, screen time, unstructured play, physical activity, and diet, to consider laboratory testing for underlying medical conditions, and to offer psychotherapy first when symptoms are mild. It notes that many of these medications lack FDA-approved labeling for children and that long-term effects are not well understood. It is non-binding: no prescription changes, no mandates on families.
State Surgeon General Dr. Joseph A. Ladapo pointed the finger at incentives rather than families or physicians: “But unfortunately, the structure of the system incentivizes fast prescriptions, patient throughput, and not delving into why people are actually having problems, and that’s a huge problem.” The state’s health care administration drew its own boundary. “Psychotropic medications can play an important role in treatment when they are clinically appropriate and medically necessary, but they should never be used as a substitute for individual therapy and other psychosocial care options,” said Agency for Health Care Administration Secretary Shevaun L. Harris.
The scale explains the attention. Coverage of the announcement cited federal survey data showing nearly 15 percent of children ages 5 to 17 received mental health treatment in the previous year, with about 8 percent taking medication and 11.5 percent receiving therapy or counseling.
Author Quote"
Parents deserve access to clear information about the benefits, risks, and available alternatives so they can make informed decisions regarding their children’s health.
"
What the coverage gets wrong
Most coverage sorted this story into one of two bins: a state undermining children’s mental health care, or a state standing up to overprescribing. Both bins bury the evidence. The American Academy of Pediatrics’ 2019 guideline already places behavior-first care ahead of medication for children ages 4 to 6 with its strongest evidence rating, so “evaluate and build skills first” for young children is standing pediatric guidance, not a provocation. The same guideline recommends medication plus behavioral support for ages 6 to 12, so blanket avoid-medication messaging overshoots the evidence too, which is the substance of AACAP’s warning. For a parent, the takeaway is neither slogan: it is that a thorough evaluation, skill-building alongside any prescription, and supervised changes only are what the evidence has supported all along.
The part both sides skip: much of this was already the guideline
Here is what the outrage frame misses. Evaluate first, build skills first, medicate second for young children is not a fringe position. The American Academy of Pediatrics’ own clinical practice guideline for attention challenges, updated in 2019, makes parent training in behavior management the first-line approach for children ages 4 to 6, and gives that recommendation its strongest evidence rating. Asking about sleep, screens, and play is not ideology either. The U.S. Surgeon General’s 2023 advisory linked more than three hours of daily social media to a doubled risk of depression and anxiety symptoms in adolescents, and a 2024 meta-analysis of 577 studies in JAMA Network Open tied excessive screen media use to poorer mental health in children. A thorough look at a child’s daily life before medicating is what attention science has pointed toward for years.
Now the part the cheerleading frame misses. The same AAP guideline recommends FDA-approved medication together with behavioral support for children 6 to 12, because that combination is where the evidence sits for school-age children. A blanket message to avoid medication goes further than the evidence it borrows from. That gap is what alarmed the American Academy of Child and Adolescent Psychiatry, which warned in May that messaging which “broadly and imprecisely challenges established psychiatric diagnoses and evidence-based treatments” puts children and families at risk.
Notice that the two camps agree on more than they admit. Nobody defends the fifteen-minute visit that ends in a prescription without a full evaluation. Nobody credible argues medication alone builds the skills a struggling child needs. The real villain is not a pill or a guideline. It is a system whose incentives reward throughput over understanding, and a public debate that hands parents slogans where an individual evaluation belongs.
Key Takeaways:
1
The news: Florida urges full evaluations, lifestyle review, and therapy before psychiatric medication for ages 5 to 17.
2
The overlap: Pediatric guidelines already put behavior-first care ahead of medication for young children.
3
The risk: Blanket avoid-medication messaging replaces the individual evaluation every child deserves.
What this means for your family
First, the hard rule, stated by every side of this debate including Florida’s own guidance: never stop a child’s psychiatric medication abruptly or without medical supervision. The guidance itself recommends gradual, supervised reduction where reduction is appropriate. If your child takes medication and it is working, this announcement asks nothing of you.
Second, use the moment. Whatever state you live in, the strongest idea inside this guidance is a set of questions any parent is entitled to ask. Before a prescription: what did the evaluation cover, and did it include sleep, vision and hearing, screen habits, physical activity, and stressors at school and home? Alongside any prescription: what therapy or skill-building comes with it, since medication quiets symptoms while skills grow capability? And after: how will we measure whether this is working, and when do we revisit it? A provider who welcomes those questions is the provider you want.
Third, hold both slogans at arm’s length. A child who struggles with focus or anxiety is not broken, and neither medication nor its absence settles who that child becomes. Skills are built by practice, confidence is built by wins, and the adults asking careful questions are the ones who make both happen. That job was never Tallahassee’s or any agency’s. It belongs to the people in the room with the child.
Author Quote"
Psychotropic medications can play an important role in treatment when they are clinically appropriate and medically necessary, but they should never be used as a substitute for individual therapy and other psychosocial care options.
"
Here is the value under this story: nobody will ever advocate for your child as hard as you will, and no state guidance, in any direction, replaces the adult asking careful questions in the exam room. The villain is not medication and it is not caution. It is a system that rewards fifteen-minute throughput over understanding a child, and a debate that hands parents slogans instead of evaluations. Walk in with questions, insist on skill-building alongside whatever you decide, and keep building at home. Learning Success All Access gives you the structured, science-backed skill-building side of that equation, starting today.
Is Your Child Struggling in School?
Get Your FREE Personalized Learning Roadmap
Comprehensive assessment + instant access to research-backed strategies
